Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Open Access
- 25 October 2023
- journal article
- review article
- Published by MDPI AG in Infectious Disease Reports
- Vol. 15 (6) , 662-678
Abstract
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the context of expanding the therapeutic armamentarium against COVID-19, molnupiravir (Lagevrio) and ritonavir-boosted nirmatrelvir (Paxlovid) were developed, constituting the first effective oral treatments against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this narrative review, we retrospectively inquired into the clinical trials and real-world studies investigating the efficacy of these agents. Overall, clinical trials and real-world studies have demonstrated the efficacy of both agents in reducing hospitalization and death rates in COVID-19 patients. As per current recommendations, their use is suggested in patients with mild to moderate symptoms who are at high risk of developing severe disease. Nevertheless, limited data exist regarding their efficacy in specific subpopulations, such as immunocompromised patients, those with severe kidney disease, pregnant women, and children.Keywords
This publication has 86 references indexed in Scilit:
- The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infectionAntiviral Research, 2019
- Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial VirusesAntimicrobial Agents and Chemotherapy, 2018
- Characterization of β- d - N 4 -Hydroxycytidine as a Novel Inhibitor of Chikungunya VirusAntimicrobial Agents and Chemotherapy, 2017
- Identification of a New Ribonucleoside Inhibitor of Ebola Virus ReplicationViruses, 2015
- Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review.2013
- RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complexProceedings of the National Academy of Sciences, 2012
- Lopinavir/ritonavir in the treatment of HIV-1 infection: a reviewTherapeutics and Clinical Risk Management, 2008
- Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in CultureAntimicrobial Agents and Chemotherapy, 2003
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995